Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine versus S-1 with local radiotherapy in elderly esophageal squamous cell carcinoma
ChiCTR1900021069Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing Capecitabine plus local radiotherapy with S-1 plus local radiotherapy (2 arms). Primary endpoints: progression-free survival, overall survival and 3 more. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
capecitabinetegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900021069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021069.